Must-See Panels at Medical Innovation Summit 2017

Tackling hard questions on genomics/precision medicine

Now in its 15th year, Cleveland Clinic’s Medical Innovation Summit is renowned for thought-provoking panels, lively discussions with influential CEOs, and the latest technologies ready to shake up healthcare’s status quo.

Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy

Register now for MIS2017, October 23–25, in Cleveland, Ohio, and join thousands of the brightest leaders from around the world in discussing investable technologies in genomics and precision medicine. Here are a few of the headliner panels not to miss:

The State of Healthcare Innovation: A Pharma Perspective
Monday, October 23, 2017 | 1:30–2:30 p.m.
When it comes to drug pricing, healthcare is still in gridlock. While hospitals are working to streamline care and remove costs, the drug industry is putting higher and higher prices on medications. Pharma companies contend that they are simply accounting for the tremendous resources invested in R&D. Providers, of course, want to prescribe the best treatment for their patients, regardless of price. Yet, insurance companies and formulary companies are hesitant, and often unable, to pay the exorbitant prices.

To add complication, the industry is now on the verge of exciting genomic innovation, with recent firsts reported in gene therapy and gene editing. These new treatments, however, are the result of many years and millions of dollars in R&D. The price tags are bound to be significant.

Panelists from across big pharma will attempt to get to the bottom of these issues. Speakers will focus on the collaborations and creative thinking needed to break the stalemate, and also what’s needed to take medical innovation to new levels.

Moderator: Bertha Coombs, Reporter, CNBC
Toby Cosgrove, MD, CEO & President, Cleveland Clinic
Ruud Dobber, PhD, President, AstraZeneca US, and Executive Vice President, North America
Freda C. Lewis-Hall, MD, CMO, Pfizer
Stephen Ubl, President & CEO, PhRMA

Hype, Hope, and the Bottom Line: Reimbursement Strategies for Genomic Innovation
Monday, October 23, 2017 | 2:30–3:25 p.m.
In a time of value-based care, genomic testing can be expensive, especially if we want to scale these tests to healthy populations. Yet, these tests may hold the keys to managing and eliminating some of the most debilitating diseases. So, who should foot the bill?

Consumers may be the first. The recent FDA approval of consumer genetic tests is opening the door to a new age of medicine. Consumers are demanding care due to their own findings and interpretations, regardless of a doctor’s recommendation. All of these possibilities brought on by genomic testing have clinicians, insurance companies and government leaders reflecting on payment strategies, all in the midst of debates about keeping care affordable.

Advertising Policy

Get a glimpse of how stakeholders are planning to react to these pressures, how they can collaborate to ensure better care and lower costs, and how genomics companies can successfully navigate a market that resides on the cutting-yet-uncertain-edge of innovation.

Stephen MillerMD, CMO, Express Scripts
Phil Febbo, MD, Chief Medical Officer, Genomic Health, Inc.
Alan Wright, MD, CMO, Roche Diagnostics
Chip Parkinson, EVP, Reimbursement, Myriad
David Flannery, MD, Medical Director, American College of Medical Genetics and Genomics

Precision Medicine Policy: Can the Government Cure Cancer?
Tuesday, October 24, 2017 | 9:45–10:35 a.m.
One year has passed since former Vice President Joe Biden urged MIS2016 attendees to act with the “urgency of now” in the global fight against cancer. He laid out the need for radical collaborations at the federal level that could enable data sharing, clinical trial redesign, the use of supercomputers and precision medicine to take this fight to a new level.

But is curing cancer a realistic goal? And can the government really play a leading role in this fight?

The answers are never simple. For example, our ability to classify and target specific cancer is getting more complex as we dig deeper into each tumor’s makeup. While gene editing and therapies are showing promise, there is also a new fear of going too far. And one particular question always lurks: Can the government guarantee the resources and resolve required for an enduring battle with such a relentless foe?

MIS2017 will tackle these questions and explore tactics with leaders from across the federal government.

Moderator: Reed Tuckson, MD, Tuckson Health Connections
Anna Abram, Deputy Commissioner for Policy, Planning, Legislation & Analysis, FDA
Brian Bolwell, MD, Chair, Taussig Cancer Institute, Cleveland Clinic
Eric Green, MD, PhD, Director, NIH National Human Genome Research Institute
David Shulkin, MD, Secretary, Veterans Affairs

Advertising Policy

Destiny-Changing Technologies: Making Sense of Gene Therapy, Gene Silencing, and Gene Editing Markets
Wednesday, October 25, 2017 | 10:15–11:05 a.m.
With the recent recommendation to approve a new gene therapy aimed at leukemia and lymphoma, the national media is buzzing about what this means for a host of other diseases and technologies. It wasn’t long ago that “gene therapy” represented the flaws and dangers of re-engineering genes and immune systems to fight disease. Throughout its hiatus, researchers have been working on a host of safer, more effective techniques resulting in potential treatments for blindness, hemophilia, and CALD.

While we may be at the dawn of a new era of medicine, it is difficult to predict the market reaction, given the six-figure price tag of these therapies. There also are questions about long-term side effects.

In addition to gene therapy or gene “silencing” markets, there is a similar mad dash happening in gene editing or “CRISPR” markets. These technologies hold the promise to eliminate genetic diseases like Huntington’s disease and some forms of cancer. Yet, with all this potential, we are rapidly approaching an ethical line that was recently only in the minds of science fiction writers.

Get a closer look at how front-line experts are simultaneously navigating the science, the markets, and the ethical questions of these technologies.

Moderator: Casey Cunningham, MD, Chief Scientific Officer, Santé Ventures
Katrine Bosley, CEO, Editas Medical
Michael Severino, MD, EVP, R&D, Chief Scientific Officer, AbbVie
Akshay Vaishnaw, MD, PhD, EVP, R&D, Alnylam